Dr. David Sidransky Appointed Director of Champions Biotechnology, Inc.
Dr. Sidransky, 47, is a renowned oncologist and research scientist namedand profiled by TIME magazine in 2001 as one of the top physicians andscientists in America, recognized for his work with early detection of cancer.Dr. Sidransky is one of the five most highly cited researchers in clinical andmedical journals in the world, in the field of oncology during the pastdecade, with over 300 peer-reviewed publications. He has contributed more than40 cancer reviews and chapters. Dr. Sidransky is a founder of a number ofbiotechnology companies and holds numerous biotechnology patents.
Dr. Sidransky has served as Vice Chairman of the Board of Directors, andpresently is a director of ImClone. He is a Vice Chairman of Alfacell andserves on the Board of Directors of Xenomics. He is serving and has served onscientific advisory boards of MedImmune, Roche, Amgen and Veridex, LLC (aJohnson & Johnson diagnostic company), among others.
Dr. Sidransky serves as Director (2005-2008) of American Association forCancer Research (AACR). He was the chairperson of the first (September 2006)and is the chairperson of the second (September 2007) AACR InternationalConference on Molecular Diagnostics in Cancer Therapeutic Development:Maximizing Opportunities for Individualized Treatment.
Dr. Sidransky is the recipient of a number of awards and honors, includingthe 1997 Sarstedt International Prize from the German Society of ClinicalChemistry, the 1998 Alton Ochsner Award Relating Smoking and Health by theAmerican College of Chest Physicians and the 2004 Hinda and Richard RosenthalAward from the American Association of Cancer Research.
"We are very pleased and delighted to announce that Dr. David Sidranskyhas been appointed to serve as a Director of the Company" said James Martell,Chairman, CEO and President of Champions Biotechnology. "Dr. Sidransky is acreative, out-of-the box thinker with wide-ranging academic and businessbackground and extensive contacts with the pharmaceutical industry, academiaand government. His depth and breadth of experience will be invaluable to us."
Champions Biotechnology is actively engaged in pursuit of additionalopportunities to grow and strengthen the company.
About Champions Biotechnology, Inc.
Champions Biotechnology is a twenty two year old publicly traded companythat beginning in January 2007, changed its business direction to focus onbiotechnology. The Company is engaged in the acquisition and early stagedevelopment of a portfolio of new therapeutic drug candidates, in theacquisition and development of novel technologies and in providingadministrative services in the field of oncology that the Company hopes willimprove methods of and approaches to disease treatment.
Champions Biotechnology plans to develop a portfolio of new therapeuticdrug candidates through pre-clinical trials and possibly early phase ("firstin man") clinical trials. If therapeutic drug candidates reach this earlystage of development, Champions Biotechnology intends to partner with, sell orlicense them to pharmaceutical and/or biotechnology companies, as appropriate.Management believes this strategy will enable Champions Biotechnology toleverage the competencies of these partners or licensees to maximize ChampionsBiotechnology's return on investment in a relatively short time frame.Champions Biotechnology believes that this model is unlike that of typical newbiotechnology companies that look to bring the process of drug developme
You May Also Like